|By Marketwired .||
|February 13, 2014 07:15 PM EST||
YOKNEAM, ISRAEL -- (Marketwired) -- 02/13/14 -- Lumenis Ltd. today announced that it has commenced an initial public offering of 6,250,000 ordinary B shares pursuant to a registration statement filed with the U.S. Securities and Exchange Commission. The underwriters will be granted a 30-day option to purchase up to 937,500 additional ordinary B shares from the selling shareholders. The initial public offering price is currently expected to be between $15.00 and $17.00 per ordinary B share. The ordinary B shares are expected to trade on the Nasdaq Global Market.
Goldman, Sachs & Co., Credit Suisse Securities (USA) LLC and Jefferies LLC will serve as joint book-running managers for the proposed offering. Wells Fargo Securities, LLC will serve as co-manager.
The offering will be made only by means of a prospectus. A preliminary prospectus for the offering, when available, may be obtained from Goldman, Sachs & Co., via telephone: (866) 471-2526; facsimile: (212) 902-9316; email: email@example.com; or standard mail at Goldman, Sachs & Co., Attn.: Prospectus Department, 200 West Street, New York, NY, 10282; Credit Suisse Securities (USA) LLC, via telephone: (800) 221-1037; email: firstname.lastname@example.org; or standard mail at Credit Suisse Securities (USA) LLC, Attn.: Prospectus Dept., One Madison Avenue, New York, NY 10010; and Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022; telephone: 877-547-6340; email: Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy these securities be accepted prior to the time the registration statement becomes effective.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Lumenis Ltd.
Lumenis is a global leader in the field of minimally-invasive clinical solutions for the surgical, ophthalmic and aesthetic markets, and has developed and commercialized innovative energy-based technologies, including laser, intense pulsed light (IPL) and radio-frequency (RF) technologies.
Goldman, Sachs & Co.
via telephone: (866) 471-2526
facsimile: (212) 902-9316
or standard mail at Goldman, Sachs & Co.
Attn.: Prospectus Department, 200 West Street
New York, NY, 10282
Credit Suisse Securities (USA) LLC
via telephone: (800) 221-1037
or standard mail at Credit Suisse Securities (USA) LLC
Attn.: Prospectus Dept.
One Madison Avenue
New York, NY 10010
and Jefferies LLC
Attention: Equity Syndicate Prospectus Department
520 Madison Avenue, 12th Floor
New York, NY 10022